Search PubMed⌕ Search

PubMed · 16639992

Classification of error in anatomic pathology: a proposal for an evidence-based standard.

Abstract

Error in anatomic pathology (EAP) is an appropriate problem to consider using the disease model with which all pathologists are familiar. In analogy to medical diseases, diagnostic errors represent a complex constellation of often-baffling deviations from the "normal" condition. Ideally, one would wish to approach such "diseases of diagnosis" with effective treatments or preventative measures, but interventions in the absence of a clear understanding of pathogenesis are often ineffective or even harmful. Medical therapy has its history of "bleeding and purging," and error-prevention has a history of "blaming and shaming." The urge to take action in dealing with either medical illnesses or diagnostic failings is, of course, admirable. However, the principle of primum non nocere should guide one's action in both circumstances. The first step in using the disease model to address EAP is the development of a valid taxonomy to allow for grouping together of abnormalities that have a similar pathogenesis. It is apparent that disease categories such as "tumor" are not valuable until they are further refined by precise and accurate classification. Likewise, "error" is an impossibly broad concept that must be parsed into meaningful subcategories before it can be understood with sufficient clarity to be prevented. One important EAP subtype that has been particularly difficult to understand and classify is knowledge-based interpretative (KBI) error. Not only is the latter sometimes confused with distinctly different error types such as human lapses, but there is danger of mistaking system-wide problems (eg, imprecise or inaccurate diagnostic criteria) for the KBI errors of individual pathologists. This paper presents a theoretically-sound taxonomic system for classification of error that can be used for evidence-based categorization of individual cases. Any taxonomy of error in medicine must distinguish between the various factors that may produce mistakes, and importantly, whether they are individual, small system (e.g., my histology laboratory), or big system (e.g., published diagnostic criteria). Because no overarching governing agency exists to coordinate this initiative, the recognition of need and effective implementation of EAP counter-measures must emanate from our specialty group itself.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Elliott Foucar. 2005. Classification of error in anatomic pathology: a proposal for an evidence-based standard.. https://doi.org/10.1053/j.semdp.2006.02.001

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Assessment of blinding in pharmacotherapy and noninvasive neuromodulation randomized controlled trials for neuropathic pain in adults.

In randomized controlled trials (RCTs), study participants and research personnel are often blinded to minimize biases related to knowing treatment allocation. To determine if blinding was effective, participants may be asked which treatment they believe they received ("treatment guess"). This descriptive review characterized blinding assessment (BA) reporting in pharmacotherapy and neuromodulation neuropathic pain RCTs. Of 288 papers, 36 (12.5%) reported a BA. One paper reported the results of 2 studies, so in total 37 studies with a BA were assessed. Of these, 19 were crossover, 17 parallel, and 1 partial crossover in design. All 37 studies assessed participant blinding, and 10 also assessed investigator blinding. Approximately 27% included an "unsure" answer option for treatment guess, and 38% asked the reason for the guess. There were no clear patterns in BA reporting across time nor based on treatment type. Seventeen trials provided sufficient data to calculate Bang Blinding Index (BI) to determine blinding success. Participants remained blinded (BI = 0 &#xb1; 0.2) in 10/17 placebo and 10/17 treatment arms, 6 placebo and 5 treatment arms had a BI > 0.2 suggesting possible unblinding, whereas 1 placebo and 2 treatment arms had a BI < -0.2 suggesting misinformed guessing. Overall, we found that BAs are done in a minority of published neuropathic pain trials and with variable methodology. Given the importance of minimizing risk of bias because of treatment unblinding, future studies should consider including BAs, and further consensus building is necessary to determine if and how BAs should be conducted and interpreted in analgesic clinical trials.

Bias↗

A residuals-based transition model for longitudinal analysis with estimation in the presence of missing data.

We propose a transition model for analysing data from complex longitudinal studies. Because missing values are practically unavoidable in large longitudinal studies, we also present a two-stage imputation method for handling general patterns of missing values on both the outcome and the covariates by combining multiple imputation with stochastic regression imputation. Our model is a time-varying auto-regression on the past innovations (residuals), and it can be used in cases where general dynamics must be taken into account, and where the model selection is important. The entire estimation process was carried out using available procedures in statistical packages such as SAS and S-PLUS. To illustrate the viability of the proposed model and the two-stage imputation method, we analyse data collected in an epidemiological study that focused on various factors relating to childhood growth. Finally, we present a simulation study to investigate the behaviour of our two-stage imputation procedure.

Bias↗

HIV viral dynamic models with dropouts and missing covariates.

In recent years HIV viral dynamic models have received great attention in AIDS studies. Often, subjects in these studies may drop out for various reasons such as drug intolerance or drug resistance, and covariates may also contain missing data. Statistical analyses ignoring informative dropouts and missing covariates may lead to misleading results. We consider appropriate methods for HIV viral dynamic models with informative dropouts and missing covariates and evaluate these methods via simulations. A real data set is analysed, and the results show that the initial viral decay rate, which may reflect the efficacy of the anti-HIV treatment, may be over-estimated if dropout patients are ignored. We also find that the current or immediate previous viral load values may be most predictive for patients' dropout. These results may be important for HIV/AIDS studies.

Bias↗